Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00643994 · ClinicalTrials.gov registry record · NA
CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
A NA study, sponsored by Accuray Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 379
- Enrollment target
NCT00643994: Completed NA study, sponsored by Accuray Incorporated.
NCT00643994 is a NA study that has completed, run by Accuray Incorporated. The registered enrollment target is 379 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00643994, a NA study, has completed, sponsored by Accuray Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 379 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer.
Primary Outcome
To estimate the rates of acute and late Grade 3-5 gastrointestinal and genitourinary toxicities (adverse events \[AE\]) observed during the 5 years following CyberKnife (CK) treatment for prostate cancer. Kaplan Meier estimates for 5-yr and 10-yr are reported. Adverse events occurring within 3 months of treatment were categorized as acute toxicities, and those developing after 3 months were considered late toxicities. The rates were determined using the first Grade 3 or higher adverse event pe
Interventions
- RADIATION CyberKnife Stereotactic Radiosurgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 379 participants |
| Start Date | 2007-12 |
| Est. Completion | 2021-01-27 |
| Phase | NA |
What the finished NCT00643994 record still lists
NCT00643994 is an interventional study that assigns participants to a tested intervention. The registered 379 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which CyberKnife Stereotactic Radiosurgery is the first listed.
NCT00643994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00643994 about?
NCT00643994 is a clinical study titled "CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution". The purpose of this study is to determine the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer.
What is the current status of trial NCT00643994?
This trial is currently completed. It is a NA study. The enrollment target is 379 participants. The study started on 2007-12. Estimated completion is 2021-01-27.
What interventions are being tested in trial NCT00643994?
The interventions under investigation include: CyberKnife Stereotactic Radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT00643994?
This trial is sponsored by Accuray Incorporated, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00643994's enrollment target sits among peer trials
379 274th of 2000 higher than 1,727 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia